Lipigon (Q3 Review) - Topline Before Year-End

Redeye comments on Lipigon’s Q3 report. The topline readout of the ongoing phase IIa study of Lipisense in Q4 2025 will be a major catalyst and inform future developments.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/